Arcus Biosciences Inc.

19.98-0.7500-3.62%Vol 83.01K1Y Perf 149.94%
Oct 28th, 2020 10:25 DELAYED
BID19.85 ASK19.98
Open20.26 Previous Close20.73
Pre-Market- After-Market-
 - -%  - -%
Target Price
40.00 
Analyst Rating
Strong Buy 1.00
Potential %
102.33 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap1.30B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
42.32 
Earnings Date
3rd Nov 2020

Today's Price Range

19.5520.26

52W Range

7.1937.41

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
6.31%
1 Month
18.19%
3 Months
-7.00%
6 Months
-22.88%
1 Year
149.94%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
RCUS19.98-0.7500-3.62
AAPL112.48-4.1200-3.53
GOOG1 532.00-72.2600-4.50
MSFT205.30-7.9500-3.73
XOM31.66-1.1600-3.53
WFC20.90-0.9200-4.22
JNJ139.41-3.7400-2.61
FB271.87-11.4200-4.03
GE7.630.53007.46
JPM96.98-2.3500-2.37
Earnings HistoryEstimateReportedSurprise %
Q02 2020-0.54-0.93-72.22
Q01 2020-0.56-0.63-12.50
Q04 2019-0.49-0.3822.45
Q03 2019-0.47-0.51-8.51
Q02 2019-0.37-0.64-72.97
Q01 2019-0.33-0.41-24.24
Q04 2018-0.42-0.2833.33
Q03 2018-0.40-0.2537.50
Earnings Per EndEstimateRevision %Trend
9/2020 QR0.35-63.16Negative
12/2020 QR-0.53-12.77Negative
12/2020 FY-1.78-25.35Negative
12/2021 FY-0.92-24.32Negative
Next Report Date3rd Nov 2020
Estimated EPS Next Report0.35
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume83.01K
Shares Outstanding64.91M
Trades Count910
Dollar Volume1.95M
Avg. Volume573.07K
Avg. Weekly Volume420.56K
Avg. Monthly Volume418.48K
Avg. Quarterly Volume503.56K

Arcus Biosciences Inc. (NYSE: RCUS) stock closed at 20.73 per share at the end of the most recent trading day (a 4.49% change compared to the prior day closing price) with a volume of 623.57K shares and market capitalization of 1.30B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 108 people. Arcus Biosciences Inc. CEO is Terry Rosen.

The one-year performance of Arcus Biosciences Inc. stock is 149.94%, while year-to-date (YTD) performance is 105.25%. RCUS stock has a five-year performance of %. Its 52-week range is between 7.19 and 37.41, which gives RCUS stock a 52-week price range ratio of 42.32%

Arcus Biosciences Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 3.05, a price-to-sale (PS) ratio of 98.66, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.03%, a ROC of -36.75% and a ROE of -35.75%. The company’s profit margin is -%, its EBITDA margin is -741.20%, and its revenue ttm is $13.25 Million , which makes it $0.20 revenue per share.

Of the last four earnings reports from Arcus Biosciences Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.35 for the next earnings report. Arcus Biosciences Inc.’s next earnings report date is 03rd Nov 2020.

The consensus rating of Wall Street analysts for Arcus Biosciences Inc. is Strong Buy (1), with a target price of $40, which is +102.33% compared to the current price. The earnings rating for Arcus Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arcus Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arcus Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.78, ATR14 : 1.16, CCI20 : 90.35, Chaikin Money Flow : 0.16, MACD : 0.04, Money Flow Index : 59.97, ROC : 6.14, RSI : 55.54, STOCH (14,3) : 84.09, STOCH RSI : 1.00, UO : 55.46, Williams %R : -15.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arcus Biosciences Inc. in the last 12-months were: Robert C. Goeltz (Buy at a value of $107 849), Terry Rosen (Buy at a value of $999 314), William Grossman (Buy at a value of $1 968), Yasunori Kaneko (Option Excercise at a value of $559 300)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company which focuses on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. The company focuses on an ATP-adenosine pathway which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. The pipeline products of the company include dual and selective A2R antagonists, small-molecule and antibody programs which target solid tumors. The company operates through the single segment being the business of developing and commercializing immunotherapies.

CEO: Terry Rosen

Teplephone: +1 510 694-6200

Address: 3928 Point Eden Way, Hayward 94545, CA, USA

Number of employees: 108

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

45%55%

Bearish Bullish

75%25%

News

Stocktwits